Chi Mong Christopher Or

All Publications

• Trends in nationwide incidence of uveitis in South Korea using the National Health Insurance claims database from 2010 to 2021. Eye (London, England) Hong, E. H., Kim, J., Park, S., Cho, H., Kang, M. H., Bromeo, A., Tran, A. N., Akhavanrezayat, A., Or, C. M., Thng, Z. X., Shin, Y. U., Nguyen, Q. D. 2024

  Abstract

  To investigate the population-based incidence of uveitis and the differences between anterior and non-anterior uveitis using the comprehensive Korean National Health Insurance Service (NHIS) database.We extracted data of patients who visited the clinic and were diagnosed with uveitis (based on Korean Classification of Diseases) from 2010 to 2021. The incidence of uveitis, differences between the demographics, and the underlying co-morbidities of anterior uveitis, non-anterior uveitis, and control groups were investigated.We identified 919,370 cases with uveitis (anterior: 800,132; non-anterior: 119,238). The average incidences (per 10,000 persons) of anterior and non-anterior uveitis were 13.0 (95% confidence interval [CI], 12.9-13.0), and 1.9 (95% CI, 1.9-1.9), respectively. The incidence increased (2010: 13.0; 2019: 16.5) but decreased during the coronavirus disease (COVID-19) pandemic (2020: 15.5; 2021: 15.4). The non-anterior group was significantly associated with sex (female, odds ratio [OR]: 1.09, p < 0.0001), specific age range (40-69 years, p < 0.0001), high Charlson Comorbidity Index (p < 0.0001), high household income (p < 0.0001), and various immunologic diseases (antiphospholipid antibody syndrome, OR: 1.79, p < 0.0001; systemic lupus erythematosus, OR: 1.22, p < 0.0001; psoriasis, OR: 1.13, p < 0.0001; ulcerative colitis, OR: 1.11, p = 0.0013; tuberculosis, OR: 1.09, p < 0.0001; rheumatoid arthritis, OR: 1.05, p < 0.0001) compared with the anterior group.Using the NHIS database, we conducted the largest population-based epidemiological study on uveitis in South Korea to estimate its increasing incidence in the past decade (including changes during COVID-19 pandemic) as well as its anatomical distribution. Our results may be beneficial for estimating the national burden of uveitis.

  View details for DOI 10.1038/s41433-024-03500-8

  View details for PubMedID 39690300

  View details for PubMedCentralID 505625

• Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases. Journal of ophthalmic inflammation and infection Yavari, N., Ghoraba, H., Or, C., Thng, Z. X., Mohammadi, S. S., Karaca, I., Mobasserian, A., Akhavanrezayat, A., Le, A., Lyu, X., Khatri, A., Yoo, W. S., Feky, D. E., Than, N. T., Elaraby, O., Saengsirinavin, A. O., Zhang, X., Anover, F. A., Gupta, A. S., Halim, M. S., Jison, L. A., Nguyen, Q. D. 2024; 14 (1): 56

  Abstract

  Repository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis.Medical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed. Patient characteristics including age, sex, comorbidities, clinical findings, treatment details, and adverse events were recorded. A total of 17 eyes of 17 patients were included. Median age was 43 years old and 53% of patients were male. Mean treatment duration was 25.4 ± 15.5 months. Indications for RCI therapy were scleritis (7 anterior and 1 posterior) (47.8%), panuveitis (17.4%), retinal vasculitis (17.4%), chronic/recurrent anterior uveitis (13%), and posterior uveitis (4.35%). RCI was initiated at a dose of 40 to 80 units 3 times weekly. Given the adequate control of inflammation, RCI was successfully discontinued in four patients (23.5%). Prior to RCI therapy, 14 (82.3%) patients were on oral prednisone at an average of 10 mg daily (range 2.5-40 mg), and two (11.7%) patients discontinued prednisone immediately before initiating RCI due to side effects. After six months of therapy, the prednisone dose was reduced in four (23.5%) patients to an average of 3 mg daily (range 1-5 mg) and was stopped in eight (53%) patients. Concomitant immunomodulatory therapies (IMTs) included mycophenolate mofetil (23.5%) and methotrexate (23.5%), and adalimumab (23.5%). Ten patients were on IMTs prior to using RCI, and during the course of treatment, IMT was stopped in two patients and reduced in one. Side effects included insomnia (23%), hypertension (11.7%), lower extremity edema (11.7%), hyperglycemia (11.7%), weight gain (11.7%), and infection (5.8%).RCI may be considered as a potential therapy with acceptable tolerability for patients with non-infectious scleritis or uveitis.

  View details for DOI 10.1186/s12348-024-00428-8

  View details for PubMedID 39448433

  View details for PubMedCentralID 7492378

• Characteristics of Patients with Adalimumab therapy that were Anti-adalimumab Antibodies Positive but Later turned Negative Or, C., Hung, J., Khatri, A., Bazojoo, V., Akhavanrezayat, A., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2024

  View details for Web of Science ID 001312227707240

• Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis. Heliyon Bromeo, A. J., Karaca, I., Ghoraba, H. H., Lyu, X., Than, N. T., Ongpalakorn, P., Shin, Y. U., Uludag, G., Tran, A. N., Thng, Z. X., Do, D. V., Or, C. M., Nguyen, Q. D. 2024; 10 (9): e29313

  Abstract

  Purpose: To evaluate risk factors associated with development of anti-adalimumab antibodies (AAA) in patients with non-infectious uveitis treated with adalimumab.Methods: A retrospective, cross-sectional, case-control study was done evaluating patients with non-infectious uveitis treated with adalimumab for at least 12 months and have undergone testing for AAA levels. Demographics, clinical characteristics, grading of ocular inflammation, and previous and concomitant immunomodulatory therapy were assessed. Univariate and multivariate analysis were done to estimate odds ratio (OR) with 95% confidence intervals for the various risk factors.Results: A total of 31 patients were included in the analysis, in which 12 patients who tested positive (Group 1) were matched with 19 patients who tested negative for AAA (Group 2). The groups differed significantly in terms of sex (female) (91.7% vs 52.6%, p=0.046), presence of systemic disease (91.7% vs 42.1%, p=0.008), and presence of anterior chamber inflammation at baseline (100% vs 63.2%, p=0.026). A history of interruption in anti-TNF therapy prior to starting or restarting adalimumab was found to have an increased odds for development of AAA (OR 16.89 [2.92, 107.11], p=0.008), as well as flare-ups (reactivation of disease) during adalimumab therapy (OR 6.77 [1.80, 61.80], p=0.027). Weekly dosing of adalimumab was shown to decrease odds of AAA development (OR 0.34 [0.02, 0.70], p=0.040), while concomitant anti-metabolite therapy was not shown to be a statistically significant protective factor (OR 2.22 [0.50, 9.96], p=0.148).Conclusions: History of interruption in anti-TNF therapy and flare during adalimumab were associated with development of AAA, while weekly dosing of adalimumab was protective against AAA. Identification of those with higher risk of developing AAA may guide in clinical decision making to optimize management for these patients.

  View details for DOI 10.1016/j.heliyon.2024.e29313

  View details for PubMedID 38694084

• Repeatability of photopic negative response parameters in normal subjects using Diopsys® NOVA™ Sendino, I., Akhavanrezayar, A., Yavari, N., Perez-Alvarez, A., Karaca, I., Park, S., Khojasteh, H., Ghoraba, H., Or, C., Bromeo, A., Yasar, C., Than, N., Bajozoo, V., Uludag, G., Do, D. V., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2023

  View details for Web of Science ID 001053758300343

• Posterior Segment Ocular Findings in HLA-B27 Positive Patients with Uveitis: A Retrospective Analysis. Clinical ophthalmology (Auckland, N.Z.) Or, C., Lajevardi, S., Ghoraba, H., Park, J. H., Onghanseng, N., Halim, M. S., Hasanreisoglu, M., Hassan, M., Uludag, G., Akhavanrezayat, A., Nguyen, Q. D. 2023; 17: 1271-1276

  Abstract

  To describe the prevalence and characteristics of posterior segment manifestations in patients with HLA-B27-associated uveitis using wide field imaging.Medical records of patients diagnosed with HLA-B27-associated uveitis from a tertiary uveitis clinic were reviewed. Posterior segment involvements including but not limited to peripheral vasculitis, optic disc inflammation, and macula edema documented based on medical records and various imaging modalities including wide field fluorescein angiography and optical coherence tomography, were noted. Demographic characteristics, accompanied with systemic diseases as well as duration and chronicity of uveitis, were also evaluated. Patients with significant systemic and ocular comorbidities were excluded. Statistical analyses including chi-squared tests and paired t-tests were employed.Of the 44 patients with HLA-B27 associated uveitis, 22 patients (50%) were noted to demonstrate posterior segment involvement. Disc leakage and peripheral vasculitis were the most common findings of posterior involvement. Those with anterior chamber inflammation were found to have a significantly increased risk of posterior involvement. Those with posterior involvement were also noted to have a statistically significant decreased visual acuity. No significant association was found between documented duration of disease and posterior segment involvement.The prevalence of posterior segment involvement in HLA-B27 associated uveitis is higher compared to previous reports when evaluated with wide angle imaging modalities. Careful examination of the posterior segment is required in patients with HLA-B27 associated uveitis.

  View details for DOI 10.2147/OPTH.S408728

  View details for PubMedID 37152636

  View details for PubMedCentralID PMC10162386

• Electroretinographic findings in retinal vasculitis. The British journal of ophthalmology Ghoraba, H. H., Matsumiya, W., Or, C., Khojasteh, H., Patel, P., Karaca, I., Regenold, J., Zaidi, M., Hwang, J., Lajevardi, S., Yavari, N., Than, N. T., Park, S. W., Akhavanrezayat, A., Uludag, G., Yasar, C., Leung, L. B., Nguyen, Q. D. 2022

  Abstract

  To describe and correlate electroretinographic responses with clinical and angiographic findings in retinal vasculitis (RV).Medical records of patients with diagnosis of RV at a tertiary eye centre from December 2017 to May 2021 were reviewed. Cases in which fluorescein angiography (FFA) and full field electroretinography (ffERG) were done within 1 month were included. FFAs were graded according to the Angiography Scoring for Uveitis Working Group from 0 to 40, where 0 is normal. A novel ffERG grading system was implemented where individual waves were graded for timing and amplitude and general ffERG score was determined with 6 being a perfect score.20 patients (34 eyes) were included. Mean age was 43.9±19.8 years; 70% were female. Median best-corrected visual acuity was 0.8 (0.08-1). Mean FFA score was 12.6±6.5. Median general ffERG score was 5 (0-6). 68% and 91% of eyes had responses with general ffERG scores ≥5 and 4, respectively. Flicker timing was most commonly affected.FFA scores weakly correlated with delayed photopic cone b-wave and flicker timing (p=0.03 and 0.016, respectively). Vitreous haze moderately correlated with delayed cone b-wave timing (p<0.001), delayed flicker timing (p=0.002) and weakly correlated with lower flicker amplitude (p=0.03). Underlying systemic disease was associated with poor ffERG responses.In this study, RV was not frequently associated with severe global retinal dysfunction Higher FFA scores, and vitreous haze grading were weakly, but significantly, correlated with cone-generated ffERG responses.

  View details for DOI 10.1136/bjo-2022-321716

  View details for PubMedID 36130816

• Repeatability of electroretinogram measurements Or, C., Ghoraba, H., Zaidi, M., Akhavanrezayat, A., Regenold, J., Uludag, G., Yasar, C., Park, S., Than, N., Hwang, J., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

  View details for Web of Science ID 000844401302074

• Efficacy of infliximab and tocilizumab in non-infectious retinal vasculitis: 12-month outcomes Karaca, I., Ghoraba, H., Hwang, J., Or, C., Matsumiya, W., Uludag, G., Zaidi, M., Regenold, J., Khojasteh, H., Mobasserian, A., Park, S., Than, N., Yavari, N., Bazojoo, V., Do, D. V., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

  View details for Web of Science ID 000844437002245

• Electroretinographic findings in retinal vasculitis Ghoraba, H., Matsumiya, W., Patel, P., Or, C., Karaca, I., Regenold, J., Zaidi, M., Khojasteh, H., Hwang, J., Lajevardi, S., Yavari, N., Park, S., Akhavanrezayat, A., Mobasserian, A., Nguyen, Q. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

  View details for Web of Science ID 000844401302086

• Novel retinopathy in pediatric retinal vasculitis: long term follow up Yasar, C., Ghoraba, H., Regenold, J., Or, C., Halim, M., Uludag, G., Hwang, J., Karaca, I., Mobasserian, A., Akhavanrezayat, A., Yasar, M., Khojasteh, H., Sepah, Y. J., Do, D. V., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

  View details for Web of Science ID 000844437001051

• Spectral-domain optical coherence tomography morphological characteristics in patients with cone dystrophy Khojasteh, H., Bazvand, F., Haidari, M., Mahmoudi, A., Mohammadi, S., Esfahani, H., Mirghorbani, M., Azarkish, A., Regenold, J., Akhavanrezayat, A., Karaca, I., Park, S., Uludag, G., Or, C., Ghoraba, H., Quan Dong Nguyen ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2022

  View details for Web of Science ID 000844437005174